首页> 外国专利> COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS

COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS

机译:与抗病毒效应的组合药物对新的SARS-COV-2冠状病毒

摘要

FIELD: medicine; biotechnology; virology; immunology.;SUBSTANCE: combined drug (CD) with an antiviral effect against SARS-CoV-2 coronavirus and related viruses is presented, provided that the genetic target, against which the specific component of this drug is directed, is identical. The combined drug for the prevention or treatment of coronavirus infection caused by SARS-CoV-2 contains: (i) the effective number of siRNA molecules directed against the genome of the SARS-CoV-2 virus, represented as two complementary chains characterized by the (+G)GAAGGAAGUUCUGUUGAA(+T)(+T)dT and UUCAACAGAACUUCCUUCC(+T)(+T)dT structure, where the modified nucleotides in the sense and antisense strand are represented by the LNA modification, (ii) a dendrimer cationic peptide with transfection activity characterized by the R8K4X4K2H2KZC structure, where R is arginine; K is lysine; X is SEQ ID NO 3; H is histidine; Z is phenylalanine (F); C is cysteine or cysteine amide, (iii) a pharmacologically acceptable auxiliary agent (solvent). ;EFFECT: invention suppresses the replication of SARS-CoV-2 virus, which provides a new opportunity for treatment of COVID19 infection caused by this virus.;14 cl, 12 dwg, 9 ex
机译:领域:医学;生物技术;病毒学;免疫学。物质:提出了对SARS-COV-2冠状病毒和相关病毒的抗病毒效应的物质:抗病毒效应,条件是该药物针对该药物的特定组分的遗传目标是相同的。由SARS-COV-2引起的预防或治疗冠状病毒感染的合并药物含有:(i)针对SARS-COV-2病毒的基因组的有效数量的siRNA分子,表示为两个互补链(+ g)高曲谷uugaa(+ t)(+ t)dt和ucaacagaacuuccuucc(+ t)(+ t)dt结构,其中有意义和反义链中的改性核苷酸由LNA改性而表示,(ii)树枝状聚合物阳离子具有转染活性的肽,其特征在于R 8 k 4 x 4 k 2 h 2 KZC结构,其中R是精氨酸; k是赖氨酸; X是SEQ ID NO 3; h是组氨酸; Z是苯丙氨酸(F); C是半胱氨酸或半胱氨酸酰胺,(iii)药理学上可接受的辅助剂(溶剂)。 ;效果:发明抑制了SARS-COV-2病毒的复制,这为治疗该病毒引起的Covid19感染提供了新的机会。; 14 Cl,12 dwg,9例

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号